At 3.5% CAGR, the North America Hydrocephalus Shunts Market is projected to be worth US$ 150.64 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the North America hydrocephalus shunts market was valued at US$ 122.61 million in 2022 and is expected to reach US$ 150.64 million by 2028, registering a CAGR of 3.5% from 2022 to 2028. Increasing prevalence of hydrocephalus and increasing advancement in hydrocephalus valves are the critical factors attributed to the market expansion.

Cerebrospinal fluid (CSF) in the brain and spinal cord protects the central nervous system from injuries and infections. The accumulation of excess CSF in brain cavities adds to intracranial pressure, thereby leading to hydrocephalus. The condition may further lead to macrocephaly and cognitive dysfunctions. Hydrocephalus is more prevalent in children and infants than in the adult population. The disease is also prevalent in people aged 60 and above. According to the Hydrocephalus Association, the disease affects over 1 million Americans. Additionally, the incidence rate of hydrocephalus in the US is 1 in every 770 babies. The treatment approach of hydrocephalus highly focuses on managing CSF through medical devices named shunts. The shunt systems remove excess cerebrospinal fluid from the brain and divert it to other body parts, wherein it is absorbed as a part of the circulatory process. Thus, the high incidence of hydrocephalus drives the demand for hydrocephalus shunts, thereby boosting the North America hydrocephalus shunts market growth.

On the contrary, high cost of treatment due to shunts and revision surgeries hampers North America hydrocephalus shunts market. 

Based on age group, the North America hydrocephalus shunts market is segmented into pediatric and adults. The pediatric segment held 57.6% market share in 2022, amassing US$ 70.62 million. It is projected to garner US$ 87.34 million by 2028 to expand at 3.6% CAGR during 2022–2028.

Based on type, the North America hydrocephalus shunts market is segmented into ventriculo-peritoneal, ventriculo-atrial, ventriculo-pleural, and lumbo-peritonea. The ventriculo-peritoneal segment held 44.2% market share in 2022, amassing US$ 54.14 million. It is projected to garner US$ 67.81 million by 2028 to expand at 3.8% CAGR during 2022–2028.  

Based on product, the North America hydrocephalus shunts market is segmented into hydrocephalus valves, hydrocephalus catheters, neuronavigation systems, and others. The hydrocephalus valves segment held 62.4% market share in 2022, amassing US$ 76.56 million. It is projected to garner US$ 95.25 million by 2028 to expand at 3.7% CAGR during 2022–2028.  

Based on end user, the North America hydrocephalus shunts market is segmented into hospitals, ambulatory surgical centers, others. The hospital segment held 54.5% market share in 2022, amassing US$ 66.86 million. It is projected to garner US$ 84.13 million by 2028 to expand at 3.9% CAGR during 2022–2028.     

Based on country, the North America hydrocephalus shunts market has been categorized into US, Canada, and Mexico. Our regional analysis states that US captured 89.4% market share in 2022. It was assessed at US$ 109.61 million in 2022 and is likely to hit US$ 135.48 million by 2028, exhibiting a CAGR of 3.6% during the forecast period.            

Key players dominating the North America hydrocephalus shunts market are B. Braun Melsungen AG (CHRISTOPH MIETHKE GMBH & CO. KG); Sophysa; HpBio Próteses, inc.; Integra LifeSciences Holdings Corporation; KANEKA MEDIX CORP.; Medtronic; Natus Medical Incorporated; and Spiegelberg GmbH & Co. KG, among others.

•  In July,2019; Integra LifeSciences announced the acquisition of Arkis Biosciences Inc. a privately-held company that offers a portfolio of neurosurgical devices such as catheters. The acquisition of Arkis Biosciences strengthened Integra’s offerings in neurocritical care and Integra’s position as the world leader in advanced catheter technology.
• In May,2020; Aesculap, Inc. in partnership with The Christoph Miethke GmbH & Co. KG (MIETHKE) announced the launch of the M.blue valve in the US. The M.blue valve features advanced gravitational technology, which is incorporated with a fixed differential pressure unit in one valve. It helps to provide a simple and position-dependent solution.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com